Autosomal Recessive Polycystic Kidney (ARPKD)
1 clinical trials · Condition
◉ Watch Autosomal Recessive Polycystic Kidney (ARPKD)
| Record | Firm | Date |
|---|---|---|
| A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) (NCT04782258) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-01-23 |
Track Autosomal Recessive Polycystic Kidney (ARPKD) automatically
Every clearance here is in the API, with alerts when new ones post.